Neoadjuvant (neo) immune checkpoint blockade (ICB) in patients (Pts) with high-risk resectable metastatic melanoma (MM).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.9510
Abstract: 9510Background: Nivolumab (nivo) and combination ipilimumab (ipi) + nivo are highly active in pts with unresectable and stage IV MM. Nivo is also safe and effective adjuvant treatment for MM pts wi... read more here.
Keywords: checkpoint blockade; immune checkpoint; blockade icb; icb patients ... See more keywords